ALX Oncology Holdings Inc. (ALXO) Long-Term Debt to Capital Ratio

ALX Oncology - graphic logo of issuer ALXO

ALX Oncology Holdings (ALXO) is diversifying its biomedical risks by developing combination therapies to combat solid tumors. This chart of long-term debt levels illustrates the debt-to-equity dynamics, where the parameter is 0.07. The creation of blocker proteins ensures stable demand and patent-protected profits, while current clinical trials are fully funded by existing liquidity reserves.

Long-Term Debt to Equity: ALX Oncology (ALXO) for 07/04/2022 - 11/01/2026

Analytical breakdowns for ALX Oncology Holdings

- market price and analyst price targets:
Market Price alxoncology.com|ALXO - Price Target Chart
- market capitalization details:
Market Capitalization ALX Oncology Holdings|ALXO - Enterprise Value
- issuer book value statistics:
Accounting Value per Share ALX Oncology|ALXO - Company Book Value|Market-to-Book Ratio alxoncology.com|ALXO - Aggregate Company Assets
- debt and solvency information:
Debt to Equity ALX Oncology Holdings|ALXO - Long-Term Debt to Equity|Current Liabilities to Capital ALX Oncology Holdings Inc.|ALXO - Company Aggregate Debts|Debt to Net Assets ALX Oncology Holdings|ALXO - Company Long-Term Liabilities|Short-Term Debt ALX Oncology|Intermediate Coverage Ratio alxoncology.com
- company profitability and valuation multiples indicators:
ALXO - Net Profit
Summary company analysis:ALXO - alxoncology.com
Brand item of ALX Oncology

ALX Oncology Holdings focuses on developing oncology complexes and reserving production capacities. The long-term debt-to-equity ratio reflects the dependence of these investments on credit resources. This metric compares liabilities with maturities exceeding one year against total equity. Daily monitoring eliminates hidden debt loads during consolidation periods. Consistently low values confirm the business's financial resilience to market shocks.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Janux Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RCUS (Arcus Biosciences, Inc.)|ZYME - Long-Term Debt to Equity Ratio|TNGX - Long-Term Debt to Equity|Long-Term Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity Compass Therapeutics|Long-Term Liabilities to Capital replimune.com REPL|Long-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Long-Term Indebtedness to Equity|Pyxis Oncology - Long-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Long-Term Liabilities to Capital|IOBT: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient STRO (sutrobio.com)|INKT: Long-Term Debt to Capital|HOWL - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Immix Biopharma Inc.|Long-Term Debt to Equity Ratio cuebiopharma.com (CUE)|Long-Term Debt to Equity PDS Biotechnology (PDSB)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|MAIA Biotechnology, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Liminatus Pharma Inc. LIMN|LVTX - Long-Term Debt to Equity|NXTC (NextCure Corporation) - Long-Term Debt to Capital Ratio|leaptx.com (LPTX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Intensity Therapeutics, Inc. (INTS)|Long-Term Debt to Equity Ratio SNSE|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc